Bepotastine besilate downregulates the expression of nerve elongation factors in normal human epidermal keratinocytes.

J Dermatol Sci

Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan; Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba, 279-0021, Japan. Electronic address:

Published: April 2018

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2018.04.012DOI Listing

Publication Analysis

Top Keywords

bepotastine besilate
4
besilate downregulates
4
downregulates expression
4
expression nerve
4
nerve elongation
4
elongation factors
4
factors normal
4
normal human
4
human epidermal
4
epidermal keratinocytes
4

Similar Publications

Background: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion.

View Article and Find Full Text PDF

Purpose: To study the efficacy and toxic effects of bepotastine besilate 1.5% preservative-free (BB-PF) and olopatadine 0.2% BAK-preserved (OL-BAK) drops on the ocular surface of patients with allergic conjunctivitis.

View Article and Find Full Text PDF

Background Urticaria is a common skin disease which often causes impairment in the quality of life. The ideal drug for chronic urticaria would have antihistaminic and anti-inflammatory actions. Bepotastine besilate is a recently approved novel anti-allergic agent with multiple mechanisms of action; levocetirizine is a potent and selective second-generation H1 receptor antagonist used in the treatment of urticaria.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic urticaria is a common skin condition that causes discomfort, and there is a need for more effective treatment options like bepotastine, a second-generation antihistamine that may also help reduce eosinophil migration.
  • A study was conducted to compare the effectiveness and safety of bepotastine and levocetirizine in treating chronic urticaria, involving adult patients randomly assigned to either medication over multiple follow-ups.
  • Results showed that both medications reduced urticaria severity scores, but bepotastine had a significantly lower incidence of daytime sedation compared to levocetirizine, suggesting it might be a better option for patients concerned about side effects.
View Article and Find Full Text PDF

Background: The efficacy of rupatadine for the treatment of AR has been confirmed in numerous clinical studies, however there are very few studies on asian patients.

Objective: To assess the safety and efficacy of rupatadine fumarate in the treatment of Korean perennial allergic rhinitis (PAR) patients.

Methods: A multicenter, double-blind, randomized, placebo-controlled, comparative study of rupatadine fumarate and bepotastine besilate was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!